Ablation to Treat Atrial Fibrillation: Beyond Rhythm Control

Zak, Jody

doi:10.4037/ccn2010335

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During these procedures, patients are given varying doses of heparin which is monitored with the activated clotting time (ACT). Variations in the ACT, along with potential remnant warfarin anticoagulation, can increase risk of bleeding 45,4647,48.…”

Section: Strategies For Managing Bleeding Riskmentioning

confidence: 99%

Current strategies to minimize the bleeding risk of warfarin

Snipelisky¹,

Kusumoto²

2013

JBM

View full text Add to dashboard Cite

For many decades, the vitamin K antagonist warfarin has been the mainstay of treatment for various conditions that require anticoagulation, including atrial fibrillation. Although the efficacy of warfarin in both prevention and treatment of thrombosis has been demonstrated in numerous randomized clinical studies, one of the major concerns that remains is the risk of bleeding. Although the net benefit of warfarin has been demonstrated in large clinical trials, physicians and patients alike are often reluctant to use warfarin because of the bleeding risk. Bleeding in patients on warfarin is generally minor requiring no intervention, but the development of a major bleeding complication is associated with significant morbidity and can even be fatal. Numerous risk factors that increase the probability of having a hemorrhage while on warfarin have been identified, and bleeding risk scores have been developed. Various strategies to reduce bleeding risks have been developed and have become more important, since the use of warfarin and other anticoagulants continues to increase. This paper provides a concise review of bleeding risk factors, while outlining recommendations both physician and patients can incorporate to help reduce the risk of bleeding.

show abstract

Section: Strategies For Managing Bleeding Riskmentioning

confidence: 99%